Altor BioScience Corp-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Altor BioScience Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010848
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Altor BioScience Corp (Altor BioScience) is a clinical stage biopharmaceutical company that discovers, develops and commercializes immunotherapeutic products. The company’s pipeline products include ALT-801, ALT-836, and ALT-803. Its technologies are soluble t-cell antigen receptor, inhibitor of MHC-peptide activation of t-cells screening, IL-15 protein superagonist and scaffold technology and tissue factor antagonist technology. Altor BioScience offers reagents for research and design of anti-viral and anti cancer vaccines. The company also develops engineered cytokine technology platforms to combat cancers and infectious diseases. It provides targeted immunotherapeutic agents for inflammatory, cancer treatment, viral infections and autoimmune diseases. Altor BioScience is headquartered in Miramar, Florida, the US.

Altor BioScience Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Altor BioScience Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Altor BioScience Corp, Medical Devices Deals, 2011 to YTD 2017 9
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Altor BioScience Raises USD30 Million in Venture Financing 11
Altor BioScience Raises USD20 Million in Financing Round 12
Altor Bioscience Raises US$5.5 Million In Venture Financing 13
Altor Bioscience Raises Additional US$1 Million In Series D Financing 14
Partnerships 15
Oxis International Enters into Co-Development Agreement with Altor BioScience 15
Altor BioScience Enters into Co-Development Agreement with NantKwest 16
Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 17
Licensing Agreements 18
Altor BioScience Enters into Licensing Agreement with Shenzhen Beike Biotech for ALT-803 18
Acquisition 20
NantCell Acquires Altor BioScience 20
Altor BioScience Corp – Key Competitors 21
Altor BioScience Corp – Key Employees 22
Altor BioScience Corp – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
Apr 08, 2016: Altor BioScience Announces the Appointment of Dr. Patrick Soon-Shiong as Chairman of its Board of Directors 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Altor BioScience Corp, Pharmaceuticals & Healthcare, Key Facts 2
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Altor BioScience Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Altor BioScience Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Altor BioScience Corp, Medical Devices Deals, 2011 to YTD 2017 9
Altor BioScience Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Altor BioScience Raises USD30 Million in Venture Financing 11
Altor BioScience Raises USD20 Million in Financing Round 12
Altor Bioscience Raises US$5.5 Million In Venture Financing 13
Altor Bioscience Raises Additional US$1 Million In Series D Financing 14
Oxis International Enters into Co-Development Agreement with Altor BioScience 15
Altor BioScience Enters into Co-Development Agreement with NantKwest 16
Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 17
Altor BioScience Enters into Licensing Agreement with Shenzhen Beike Biotech for ALT-803 18
NantCell Acquires Altor BioScience 20
Altor BioScience Corp, Key Competitors 21
Altor BioScience Corp, Key Employees 22

★海外企業調査レポート[Altor BioScience Corp-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tennessee Valley Authority:企業の発電所・SWOT分析2018
    Tennessee Valley Authority - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Auswide Bank Ltd (ABA):企業の財務・戦略的SWOT分析
    Auswide Bank Ltd (ABA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • DP World Ltd:企業の戦略的SWOT分析
    DP World Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Teva Pharmaceutical Industries Ltd (TEVA):企業の財務・戦略的SWOT分析
    Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • China Longyuan Power Group Corporation Ltd (916):電力:M&Aディール及び事業提携情報
    Summary China Longyuan Power Group Corporation Ltd (CLPGC), a subsidiary of China Energy Investment Corporation Ltd, carries out design, development, construction, management and operation of wind farms. It generates and sells electricity to the local grid companies. The company also operates other …
  • Maxim Integrated Products, Inc.:企業の戦略・SWOT・財務情報
    Maxim Integrated Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Maxim Integrated Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Aurinia Pharmaceuticals Inc (AUP):企業の財務・戦略的SWOT分析
    Summary Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals), formerly Isotechnika Pharma Inc, is a clinical stage biopharmaceutical company which develops and commercializes therapies for the treatment of diseases with high unmet medical need. Its pipeline products include Voclosporin, is an inves …
  • Bank of India:企業のM&A・事業提携・投資動向
    Bank of India - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of India Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Sancilio & Company Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Sancilio & Company Inc (SCI), a subsidiary of Sancilio Pharmaceuticals Company Inc is a drug development company that develops, manufactures and markets over the counter and generic prescription products. The company provides products such as omega-3, ludent sodium fluoride chewable tablets …
  • Reliv International Inc (RELV):企業の財務・戦略的SWOT分析
    Summary Reliv International Inc (Reliv) is a nutrition company that develops, manufactures and markets nutritional supplements for basic nutrition, specific wellness needs, weight management and sports nutrition. The company’s products include Reliv Classic and Reliv NOW, a nutritional supplement wi …
  • Marina Biotech Inc (MRNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Marina Biotech Inc (Marina) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and …
  • Eu Yan Sang International Ltd:企業の戦略的SWOT分析
    Eu Yan Sang International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • New Standard Energy Ltd (NSE):企業の財務・戦略的SWOT分析
    Summary New Standard Energy Ltd (NSE), formerly Hawk Resources Ltd, is an oil and gas exploration and production company. The company carries out acquisition, exploration, and develops oil and gas; and hydrocarbon properties. It holds interest in production and development project in the Eagle Ford …
  • Sunbelt Transformer Ltd:電力:M&Aディール及び事業提携情報
    Summary Sunbelt Transformer Ltd (Sunbelt Transformer) is a provider of new and reconditioned transformers and electrical equipment for commercial and industrial markets. The company’s products include padmount transformers, substation transformers, dry-type transformers, pole-mount transformers, mot …
  • Isagen SA ESP:発電所・企業SWOT分析
    Isagen SA ESP - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Euler Hermes SA:企業の戦略・SWOT・財務分析
    Euler Hermes SA - Strategy, SWOT and Corporate Finance Report Summary Euler Hermes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Nottingham Building Society:企業の戦略・SWOT・財務情報
    Nottingham Building Society - Strategy, SWOT and Corporate Finance Report Summary Nottingham Building Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Abbott Vascular Inc-医療機器分野:企業M&A・提携分析
    Summary Abbott Vascular Inc (Abbott Vascular), formerly Perclose, Inc., a subsidiary of Abbott Laboratories, is a medical device company that develops manufactures and markets cardiovascular devices. The company offers coronary intervention, peripheral intervention, and structural heart products. It …
  • Entia Biosciences Inc (ERGO):企業の財務・戦略的SWOT分析
    Summary Entia Biosciences Inc (EBI) is a biotechnology company that provides nutrigenomics solutions for organic health, beauty and agriculture. The company’s solution includes ErgoD2, mushroom dietary supplement, and multi joint support. It offers ErgoD2 solutions such as Ergo-D2-Hemo, Ergo-D2-FLEX …
  • JPMorgan Chase & Co.:企業の戦略・SWOT・財務情報
    JPMorgan Chase & Co. - Strategy, SWOT and Corporate Finance Report Summary JPMorgan Chase & Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆